{"id":"W3168540735","doi":"10.1200/jco.2021.39.15_suppl.9502","title":"Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Progressive disease; Stage (stratigraphy); Melanoma; Surgery; Gastroenterology; Chemotherapy; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006374044,0.0004709247,0.0006070498,0.0001732584,0.0002868811,0.0004009381,0.0004092868,0.0004596636,0.001939593],"category_scores_gemma":[0.000304685,0.0003402627,0.0004960165,0.0001967821,0.000438041,0.0003930001,0.0002356282,0.001025607,0.0005468769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006879947,"about_ca_system_score_gemma":0.001070861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007308526,"about_ca_topic_score_gemma":0.002911684,"domain_scores_codex":[0.9998255,0.00007247496,0.00001177877,0.00003440179,0.00001912837,0.00003676385],"domain_scores_gemma":[0.9997779,0.00002824101,0.00004729493,0.00001494305,0.00000869296,0.0001229486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5119607,0.09578046,0.08868607,0.001148887,0.0006134236,0.0007334095,0.0003690492,0.002628774,0.1493827,0.0002324862,0.004422589,0.1440415],"study_design_scores_gemma":[0.05916794,0.8429223,0.0813029,0.00005223964,0.0003544478,0.000720216,0.0001356741,0.001443828,0.008572114,0.0001318997,0.005174924,0.00002142245],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978918,0.0005461098,0.0001088825,0.000095767,0.00002945006,0.0004804842,0.0002058171,0.00001660278,0.0006250184],"genre_scores_gemma":[0.9969643,0.0004208786,0.0005297028,0.0001863782,0.00004927298,0.0005632697,0.0003713778,0.000003567723,0.0009112038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001939593,"threshold_uncertainty_score":0.006488562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06720521001582311,"score_gpt":0.4402667250112583,"score_spread":0.3730615149954352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}